ADOPT PGx | Ignite II

Prescribing Prevalence of Medications With Potential Genotype-Guided Dosing in Pediatric Patients

Posted on December 14, 2020June 21, 2024 by Alexis

Laura B. Ramsey, PhD^1,2; Henry H. Ong, PhD³; Jonathan S. Schildcrout, PhD⁴; Yaping Shi, MS⁴; Leigh Anne Tang, BS⁵; J. Kevin Hicks, PharmD, PhD⁶; Nihal El Rouby, PharmD, PhD^7,8; Larisa H. Cavallari, PharmD⁷; Sony Tuteja, PharmD, MS⁹; Christina L. Aquilante, PharmD¹⁰; Amber L. Beitelshees, PharmD, MPH¹¹; Daniel L. Lemkin, MD, MS¹²; Kathryn V. Blake, PharmD¹³; Helen Williams, BS¹⁴; James J. Cimino, MD¹⁵; Brittney H. Davis, PharmD¹⁶; Nita A. Limdi, PharmD, PhD, MPSH¹⁶; Philip E. Empey, PharmD, PhD¹⁷; Christopher M. Horvat, MD, MHA¹⁸; David P. Kao, MD¹⁹; Gloria P. Lipori, MT, MBA²⁰; Marc B. Rosenman, MD^21,22; Todd C. Skaar, PhD²³; Evgenia Teal, MA²⁴; Almut G. Winterstein, PhD²⁵; Aniwaa Owusu Obeng, PharmD²⁶; Daria Salyakina, PhD²⁷; Apeksha Gupta, MPH²⁷; Joshua Gruber, MPH²⁷; Jennifer McCafferty-Fernandez, PhD²⁷; Jeffrey R. Bishop, PharmD, MS^28,29; Zach Rivers, PharmD³⁰; Ashley Benner, MPH³¹; Bani Tamraz, PharmD, PhD³²; Janel Long-Boyle, PharmD, PhD³²; Josh F. Peterson, MD, MPH³³; Sara L. Van Driest, MD, PhD^33,34; for the IGNITE Pharmacogenetics Working Group

JAMA Netw Open. 2020;3(12):e2029411. doi:10.1001/jamanetworkopen.2020.29411

Impact of the CYP2C19*17 Allele on Outcomes in Patients Receiving Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention

Posted on September 8, 2020June 21, 2024 by Alexis

Craig R. Lee,Cameron D. Thomas,Amber L. Beitelshees,Sony Tuteja,Philip E. Empey,James C. Lee,Nita A. Limdi,Julio D. Duarte,Todd C. Skaar,Yiqing Chen,Kelsey J. Cook,James C. Coons,Chrisly Dillon,Francesco Franchi,Jay Giri,Yan Gong,Rolf P. Kreutz,Caitrin W. McDonough,James M. Stevenson,Karen E. Weck,Dominick J. Angiolillo,Julie A. Johnson,George A. Stouffer,Larisa H. Cavallari, on behalf of the IGNITE Network Pharmacogenetics Working Group

First published: 08 September 2020 https://doi.org/10.1002/cpt.2039

Physician-Reported Benefits and Barriers to Clinical Implementation of Genomic Medicine: A Multi-Site IGNITE-Network Survey

Posted on July 24, 2018June 21, 2024 by Alexis

Journal of Personalized Medicine – To understand potential barriers and provider attitudes, we surveyed 285 physicians from five Implementing GeNomics In pracTicE (IGNITE) sites about their perceptions as to the clinical utility of genetic data as well as their preparedness to integrate it into practice.

The IGNITE network: a model for genomic medicine implementation and research

Posted on January 5, 2016June 21, 2024 by Alexis

BMC Medical Genetics – Patients, clinicians, researchers and payers are seeking to understand the value of using genomic information (as reflected by genotyping, sequencing, family history or other data) to inform clinical decision-making. However, challenges exist to widespread clinical implementation of genomic medicine, a prerequisite for developing evidence of its real-world utility.